0 XP   0   0   0

Akebia Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Akebia together

PenkeI guess you are interested in Akebia Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Akebia Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Akebia Therapeutics Inc

I send you an email if I find something interesting about Akebia Therapeutics Inc.

Quick analysis of Akebia (30 sec.)










1. Valuation of Akebia (5 min.)




Current price per share

€0.97

2. Growth of Akebia (5 min.)




Is Akebia growing?

Current yearPrevious yearGrowGrow %
How rich?$9.3m$150.4m-$122.5m-439.5%

How much money is Akebia making?

Current yearPrevious yearGrowGrow %
Making money-$23.1m-$70.6m$47.5m?
Net Profit Margin-49.4%-132.7%--

How much money comes from the company's main activities?

3. Financial Health of Akebia (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  



Fundamentals of Akebia

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

1.1. Profitability of Akebia Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Akebia earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Akebia to the Biotechnology industry mean.
  • A Net Profit Margin of -13.7% means that €-0.14 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Akebia Therapeutics Inc:

  • The MRQ is -13.7%. The company is making a huge loss. -2
  • The TTM is -49.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-13.7%TTM-49.4%+35.7%
TTM-49.4%YOY-132.7%+83.2%
TTM-49.4%5Y-95.6%+46.2%
5Y-95.6%10Y-95.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.7%-194.7%+181.0%
TTM-49.4%-272.1%+222.7%
YOY-132.7%-303.9%+171.2%
5Y-95.6%-539.0%+443.4%
10Y-95.6%-661.6%+566.0%
1.1.2. Return on Assets

Shows how efficient Akebia is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Akebia to the Biotechnology industry mean.
  • -2.1% Return on Assets means that Akebia generated €-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Akebia Therapeutics Inc:

  • The MRQ is -2.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -5.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.1%TTM-5.0%+2.9%
TTM-5.0%YOY-12.0%+7.0%
TTM-5.0%5Y-9.3%+4.3%
5Y-9.3%10Y-9.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.1%-12.6%+10.5%
TTM-5.0%-12.6%+7.6%
YOY-12.0%-10.9%-1.1%
5Y-9.3%-15.3%+6.0%
10Y-9.3%-17.7%+8.4%
1.1.3. Return on Equity

Shows how efficient Akebia is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Akebia to the Biotechnology industry mean.
  • -80.8% Return on Equity means Akebia generated €-0.81 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Akebia Therapeutics Inc:

  • The MRQ is -80.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -161.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-80.8%TTM-161.8%+81.0%
TTM-161.8%YOY-54.0%-107.8%
TTM-161.8%5Y-57.3%-104.6%
5Y-57.3%10Y-57.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-80.8%-15.3%-65.5%
TTM-161.8%-15.6%-146.2%
YOY-54.0%-13.2%-40.8%
5Y-57.3%-20.5%-36.8%
10Y-57.3%-20.9%-36.4%

1.2. Operating Efficiency of Akebia Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Akebia is operating .

  • Measures how much profit Akebia makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Akebia to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Akebia Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-37.3%+37.3%
TTM-37.3%YOY-109.7%+72.3%
TTM-37.3%5Y-80.8%+43.5%
5Y-80.8%10Y-80.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--313.9%+313.9%
TTM-37.3%-265.1%+227.8%
YOY-109.7%-331.0%+221.3%
5Y-80.8%-515.2%+434.4%
10Y-80.8%-609.4%+528.6%
1.2.2. Operating Ratio

Measures how efficient Akebia is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.04 means that the operating costs are €1.04 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is 1.037. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.753. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.037TTM1.753-0.716
TTM1.753YOY2.951-1.197
TTM1.7535Y2.669-0.916
5Y2.66910Y2.6690.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0373.013-1.976
TTM1.7533.644-1.891
YOY2.9514.501-1.550
5Y2.6696.353-3.684
10Y2.6698.330-5.661

1.3. Liquidity of Akebia Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Akebia is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.48 means the company has €1.48 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is 1.482. The company is just able to pay all its short-term debts.
  • The TTM is 1.310. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.482TTM1.310+0.173
TTM1.310YOY1.730-0.420
TTM1.3105Y1.732-0.422
5Y1.73210Y1.7320.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4824.571-3.089
TTM1.3105.011-3.701
YOY1.7306.142-4.412
5Y1.7326.306-4.574
10Y1.7326.588-4.856
1.3.2. Quick Ratio

Measures if Akebia is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Akebia to the Biotechnology industry mean.
  • A Quick Ratio of 0.31 means the company can pay off €0.31 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is 0.314. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.282. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.314TTM0.282+0.032
TTM0.282YOY0.262+0.020
TTM0.2825Y0.495-0.213
5Y0.49510Y0.4950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3143.923-3.609
TTM0.2824.516-4.234
YOY0.2625.772-5.510
5Y0.4955.816-5.321
10Y0.4956.032-5.537

1.4. Solvency of Akebia Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Akebia assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Akebia to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.97 means that Akebia assets are financed with 97.3% credit (debt) and the remaining percentage (100% - 97.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is 0.973. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.943. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.973TTM0.943+0.030
TTM0.943YOY0.750+0.193
TTM0.9435Y0.640+0.303
5Y0.64010Y0.6400.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9730.311+0.662
TTM0.9430.298+0.645
YOY0.7500.269+0.481
5Y0.6400.377+0.263
10Y0.6400.409+0.231
1.4.2. Debt to Equity Ratio

Measures if Akebia is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Akebia to the Biotechnology industry mean.
  • A Debt to Equity ratio of 3,666.1% means that company has €36.66 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is 36.661. The company is unable to pay all its debts with equity. -1
  • The TTM is 23.500. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ36.661TTM23.500+13.161
TTM23.500YOY3.427+20.073
TTM23.5005Y6.271+17.230
5Y6.27110Y6.2710.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ36.6610.362+36.299
TTM23.5000.361+23.139
YOY3.4270.277+3.150
5Y6.2710.425+5.846
10Y6.2710.460+5.811

2. Market Valuation of Akebia Therapeutics Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Akebia generates.

  • Above 15 is considered overpriced but always compare Akebia to the Biotechnology industry mean.
  • A PE ratio of -12.22 means the investor is paying €-12.22 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Akebia Therapeutics Inc:

  • The EOD is -25.345. Company is losing money. -2
  • The MRQ is -12.216. Company is losing money. -2
  • The TTM is -3.270. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-25.345MRQ-12.216-13.130
MRQ-12.216TTM-3.270-8.946
TTM-3.270YOY-7.282+4.012
TTM-3.2705Y-14.078+10.808
5Y-14.07810Y-14.0780.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-25.345-6.313-19.032
MRQ-12.216-7.248-4.968
TTM-3.270-8.522+5.252
YOY-7.282-19.704+12.422
5Y-14.078-18.354+4.276
10Y-14.078-18.137+4.059
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Akebia.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Akebia Therapeutics Inc:

  • The MRQ is -6.587. Very Bad. -2
  • The TTM is -1.702. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-6.587TTM-1.702-4.886
TTM-1.702YOY-7.292+5.590
TTM-1.7025Y-7.815+6.113
5Y-7.81510Y-7.8150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.587-4.301-2.286
TTM-1.702-6.130+4.428
YOY-7.292-13.925+6.633
5Y-7.815-12.463+4.648
10Y-7.815-11.860+4.045

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Akebia is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 9.88 means the investor is paying €9.88 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Akebia Therapeutics Inc:

  • The EOD is 20.489. Seems overpriced? -1
  • The MRQ is 9.875. Seems overpriced? -1
  • The TTM is 5.106. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD20.489MRQ9.875+10.614
MRQ9.875TTM5.106+4.769
TTM5.106YOY3.721+1.385
TTM5.1065Y4.098+1.008
5Y4.09810Y4.0980.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.4891.808+18.681
MRQ9.8752.028+7.847
TTM5.1062.338+2.768
YOY3.7213.951-0.230
5Y4.0983.697+0.401
10Y4.0983.952+0.146
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Akebia Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.023-0.085+272%-0.216+849%0.002-1017%0.002-1017%
Book Value Growth--0.6740.906-26%0.756-11%1.061-36%1.061-36%
Book Value Per Share--0.0470.141-67%0.759-94%1.310-96%1.310-96%
Book Value Per Share Growth--0.6740.906-26%0.756-11%1.061-36%1.061-36%
Current Ratio--1.4821.310+13%1.730-14%1.732-14%1.732-14%
Debt To Asset Ratio--0.9730.943+3%0.750+30%0.640+52%0.640+52%
Debt To Equity Ratio--36.66123.500+56%3.427+970%6.271+485%6.271+485%
Dividend Per Share----0%-0%-0%-0%
Eps---0.038-0.117+206%-0.356+836%-0.307+708%-0.307+708%
Eps Growth--1.8540.917+102%1.026+81%0.816+127%0.816+127%
Free Cash Flow Per Share---0.276-0.092-67%-0.319+16%-0.207-25%-0.207-25%
Free Cash Flow Per Share Growth---1.6170.932-274%0.706-329%-0.113-93%-0.113-93%
Free Cash Flow To Equity Per Share---0.276-0.074-73%-0.150-45%-0.082-70%-0.082-70%
Free Cash Flow To Equity Per Share Growth---62.995-14.926-76%0.560-11350%-3.601-94%-3.601-94%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---8.832--------
Intrinsic Value_10Y_min---13.070--------
Intrinsic Value_1Y_max---0.445--------
Intrinsic Value_1Y_min---0.837--------
Intrinsic Value_3Y_max---1.672--------
Intrinsic Value_3Y_min---2.940--------
Intrinsic Value_5Y_max---3.303--------
Intrinsic Value_5Y_min---5.491--------
Net Profit Margin---0.137-0.494+261%-1.327+869%-0.956+599%-0.956+599%
Operating Margin----0.3730%-1.0970%-0.8080%-0.8080%
Operating Ratio--1.0371.753-41%2.951-65%2.669-61%2.669-61%
Pb Ratio20.489+52%9.8755.106+93%3.721+165%4.098+141%4.098+141%
Pe Ratio-25.345-107%-12.216-3.270-73%-7.282-40%-14.078+15%-14.078+15%
Peg Ratio---6.587-1.702-74%-7.292+11%-7.815+19%-7.815+19%
Price Per Share0.965+52%0.4650.446+4%2.588-82%3.992-88%3.992-88%
Price To Total Gains Ratio-42.431-107%-20.451-5.589-73%-12.882-37%30.313-167%30.313-167%
Profit Growth--1.8540.917+102%1.026+81%0.816+127%0.816+127%
Quick Ratio--0.3140.282+11%0.262+20%0.495-37%0.495-37%
Return On Assets---0.021-0.050+134%-0.120+459%-0.093+333%-0.093+333%
Return On Equity---0.808-1.618+100%-0.540-33%-0.573-29%-0.573-29%
Revenue Growth--1.1271.151-2%1.020+11%1.059+6%1.059+6%
Total Gains Per Share---0.023-0.085+272%-0.216+849%0.002-1017%0.002-1017%
Total Gains Per Share Growth--1.9071.114+71%0.946+102%1.128+69%1.128+69%
Usd Book Value--9338163.14727891290.062-67%150470175.002-94%259808513.360-96%259808513.360-96%
Usd Book Value Change Per Share---0.024-0.091+272%-0.232+849%0.003-1017%0.003-1017%
Usd Book Value Per Share--0.0510.151-67%0.817-94%1.410-96%1.410-96%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.041-0.126+206%-0.384+836%-0.331+708%-0.331+708%
Usd Free Cash Flow---54656542.788-18309477.025-67%-63230020.128+16%-41012990.739-25%-41012990.739-25%
Usd Free Cash Flow Per Share---0.297-0.099-67%-0.343+16%-0.223-25%-0.223-25%
Usd Free Cash Flow To Equity Per Share---0.297-0.080-73%-0.162-45%-0.088-70%-0.088-70%
Usd Price Per Share1.038+52%0.5000.480+4%2.784-82%4.296-88%4.296-88%
Usd Profit---7548898.318-23130995.965+206%-70680958.696+836%-60958532.382+708%-60958532.382+708%
Usd Revenue--55157337.02273120456.358-25%53372570.345+3%68303514.485-19%68303514.485-19%
Usd Total Gains Per Share---0.024-0.091+272%-0.232+849%0.003-1017%0.003-1017%
 EOD+2 -3MRQTTM+19 -19YOY+21 -175Y+11 -2710Y+11 -27

3.2. Fundamental Score

Let's check the fundamental score of Akebia Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-25.345
Price to Book Ratio (EOD)Between0-120.489
Net Profit Margin (MRQ)Greater than0-0.137
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.314
Current Ratio (MRQ)Greater than11.482
Debt to Asset Ratio (MRQ)Less than10.973
Debt to Equity Ratio (MRQ)Less than136.661
Return on Equity (MRQ)Greater than0.15-0.808
Return on Assets (MRQ)Greater than0.05-0.021
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Akebia Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5050.483
Ma 20Greater thanMa 501.028
Ma 50Greater thanMa 1000.776
Ma 100Greater thanMa 2000.757
OpenGreater thanClose0.965
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2021-12-312022-03-312022-06-302022-09-302022-12-31
Cost of Revenue  46,770-17,65529,115-11,83817,27817,97135,249-38,123-2,874



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets351,830
Total Liabilities342,488
Total Stockholder Equity9,342
 As reported
Total Liabilities 342,488
Total Stockholder Equity+ 9,342
Total Assets = 351,830

Assets

Total Assets351,830
Total Current Assets184,949
Long-term Assets184,949
Total Current Assets
Cash And Cash Equivalents 90,466
Net Receivables 39,180
Inventory 21,762
Other Current Assets 33,541
Total Current Assets  (as reported)184,949
Total Current Assets  (calculated)184,949
+/-0
Long-term Assets
Goodwill 55,053
Intangible Assets 72,084
Long-term Assets Other 5,372
Long-term Assets  (as reported)166,881
Long-term Assets  (calculated)132,509
+/- 34,372

Liabilities & Shareholders' Equity

Total Current Liabilities124,756
Long-term Liabilities217,732
Total Stockholder Equity9,342
Total Current Liabilities
Short Long Term Debt 32,000
Accounts payable 18,021
Total Current Liabilities  (as reported)124,756
Total Current Liabilities  (calculated)50,021
+/- 74,735
Long-term Liabilities
Long term Debt 34,078
Capital Lease Obligations Min Short Term Debt33,705
Long-term Liabilities Other 110,637
Long-term Liabilities  (as reported)217,732
Long-term Liabilities  (calculated)178,420
+/- 39,312
Total Stockholder Equity
Total Stockholder Equity (as reported)9,342
Total Stockholder Equity (calculated)0
+/- 9,342
Other
Capital Stock2
Common Stock Shares Outstanding 184,136
Net Invested Capital 75,420
Net Working Capital 60,193



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-30
> Total Assets 
413,781
403,826
996,540
890,793
823,528
795,220
771,201
787,719
745,174
676,143
644,139
628,703
611,863
602,267
525,550
535,356
521,804
435,894
351,830
351,830435,894521,804535,356525,550602,267611,863628,703644,139676,143745,174787,719771,201795,220823,528890,793996,540403,826413,781
   > Total Current Assets 
407,417
397,526
468,275
347,233
316,396
299,008
309,533
340,756
449,102
391,000
371,437
365,017
331,076
330,084
272,010
302,687
304,163
237,512
184,949
184,949237,512304,163302,687272,010330,084331,076365,017371,437391,000449,102340,756309,533299,008316,396347,233468,275397,526407,417
       Cash And Cash Equivalents 
163,526
162,430
104,644
62,741
87,212
122,886
147,449
115,374
245,406
169,286
228,698
252,765
246,992
207,204
149,800
174,562
143,893
144,761
90,466
90,466144,761143,893174,562149,800207,204246,992252,765228,698169,286245,406115,374147,449122,88687,21262,741104,644162,430163,526
       Short-term Investments 
238,597
227,714
216,996
105,297
49,553
22,727
245
0
49,943
99,969
39,992
19,999
0
0
0
0
0
0
0
000000019,99939,99299,96949,943024522,72749,553105,297216,996227,714238,597
       Net Receivables 
832
688
16,666
48,435
28,888
29,654
38,864
105,418
39,115
24,466
28,575
37,149
36,933
53,132
55,184
68,552
91,419
28,703
39,180
39,18028,70391,41968,55255,18453,13236,93337,14928,57524,46639,115105,41838,86429,65428,88848,43516,666688832
       Other Current Assets 
0
0
0
263
363
263
2,663
395
2,795
2,795
2,795
0
0
0
2,000
0
0
0
33,541
33,5410002,0000002,7952,7952,7953952,663263363263000
   > Long-term Assets 
0
0
0
543,560
507,132
496,212
461,668
446,963
296,072
285,143
272,702
263,686
280,787
272,183
253,540
232,669
217,641
198,382
166,881
166,881198,382217,641232,669253,540272,183280,787263,686272,702285,143296,072446,963461,668496,212507,132543,560000
       Property Plant Equipment 
3,726
3,808
8,023
41,911
42,127
42,940
39,418
37,881
36,264
34,542
35,498
33,838
32,112
30,388
40,606
39,082
37,529
35,959
0
035,95937,52939,08240,60630,38832,11233,83835,49834,54236,26437,88139,41842,94042,12741,9118,0233,8083,726
       Goodwill 
0
0
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,053
55,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05355,05300
       Intangible Assets 
0
0
328,153
318,513
309,413
300,312
291,212
282,112
157,484
151,378
144,170
135,159
126,148
117,138
108,127
99,116
90,106
81,095
72,084
72,08481,09590,10699,116108,127117,138126,148135,159144,170151,378157,484282,112291,212300,312309,413318,513328,15300
       Long-term Assets Other 
0
0
0
128,083
100,539
97,907
75,985
71,917
47,271
44,170
37,981
39,636
67,474
69,604
49,754
39,418
34,953
26,275
5,372
5,37226,27534,95339,41849,75469,60467,47439,63637,98144,17047,27171,91775,98597,907100,539128,083000
> Total Liabilities 
247,857
261,285
360,612
324,414
304,172
327,658
376,444
391,355
374,914
358,181
396,521
414,812
437,232
465,117
449,094
509,240
459,504
422,041
342,488
342,488422,041459,504509,240449,094465,117437,232414,812396,521358,181374,914391,355376,444327,658304,172324,414360,612261,285247,857
   > Total Current Liabilities 
164,420
177,399
265,693
202,613
185,618
223,148
208,118
214,152
195,774
181,458
187,146
172,679
165,595
189,205
256,493
253,914
233,680
187,965
124,756
124,756187,965233,680253,914256,493189,205165,595172,679187,146181,458195,774214,152208,118223,148185,618202,613265,693177,399164,420
       Short-term Debt 
0
0
0
4,677
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000004,677000
       Short Long Term Debt 
0
0
0
4,677
0
0
0
0
0
0
0
0
0
0
97,543
97,848
98,158
65,947
32,000
32,00065,94798,15897,84897,54300000000004,677000
       Accounts payable 
4,795
12,684
42,796
15,226
19,321
64,362
39,217
54,379
29,413
40,403
41,308
30,537
41,984
28,809
33,588
19,466
24,944
19,708
18,021
18,02119,70824,94419,46633,58828,80941,98430,53741,30840,40329,41354,37939,21764,36219,32115,22642,79612,6844,795
       Other Current Liabilities 
83,720
72,183
73,051
50,383
40,316
32,142
39,830
34,886
23,529
18,034
15,214
18,253
11,869
15,692
20,906
26,940
26,209
19,184
0
019,18426,20926,94020,90615,69211,86918,25315,21418,03423,52934,88639,83032,14240,31650,38373,05172,18383,720
   > Long-term Liabilities 
0
0
0
121,801
118,554
104,510
168,326
177,203
179,140
176,723
209,375
242,133
271,637
275,912
192,601
255,326
225,824
234,076
217,732
217,732234,076225,824255,326192,601275,912271,637242,133209,375176,723179,140177,203168,326104,510118,554121,801000
       Capital Lease Obligations Min Short Term Debt
0
0
0
31,304
34,849
33,695
32,517
31,303
30,068
28,811
29,907
28,614
27,310
25,980
38,505
37,344
36,155
34,943
33,705
33,70534,94336,15537,34438,50525,98027,31028,61429,90728,81130,06831,30332,51733,69534,84931,304000
       Long-term Liabilities Other 
0
0
0
29,736
29,898
30,060
30,223
30,385
41,508
40,971
60,611
100,542
134,457
128,530
135,604
156,279
149,685
159,337
110,637
110,637159,337149,685156,279135,604128,530134,457100,54260,61140,97141,50830,38530,22330,06029,89829,736000
> Total Stockholder Equity
165,924
142,541
635,928
566,379
519,356
467,562
394,757
396,364
370,260
317,962
247,618
213,891
174,631
137,150
76,456
26,116
62,300
13,853
9,342
9,34213,85362,30026,11676,456137,150174,631213,891247,618317,962370,260396,364394,757467,562519,356566,379635,928142,541165,924
   Common Stock
1
1
1
1
1
1
1
1
1
1
1
2
2
2
1
2
2
2
0
0222122211111111111
   Retained Earnings Total Equity0000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
-459
-409
-261
-36
23
6
0
0
-9
6
13
9
6
6
6
6
6
6
0
06666669136-900623-36-261-409-459



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue292,602
Cost of Revenue-84,796
Gross Profit207,806207,806
 
Operating Income (+$)
Gross Profit207,806
Operating Expense-355,784
Operating Income-63,182-147,978
 
Operating Expense (+$)
Research Development129,114
Selling General Administrative141,874
Selling And Marketing Expenses-
Operating Expense355,784270,988
 
Net Interest Income (+$)
Interest Income-
Interest Expense-15,687
Other Finance Cost-0
Net Interest Income-15,687
 
Pretax Income (+$)
Operating Income-63,182
Net Interest Income-15,687
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-92,562-33,802
EBIT - interestExpense = -15,687
-92,562
-76,875
Interest Expense15,687
Earnings Before Interest and Taxes (EBIT)--76,875
Earnings Before Interest and Taxes (EBITDA)-63,182
 
After tax Income (+$)
Income Before Tax-92,562
Tax Provision-0
Net Income From Continuing Ops-92,562-92,562
Net Income-92,562
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-29,38015,687
 

Technicals of Akebia

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Akebia Therapeutics Inc Daily Moving Averages ChartAkebia Therapeutics Inc Daily Moving Averages Chart
1.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Let's take a look of the Moving Average Convergence/Divergence (MACD) of Akebia Therapeutics Inc:

  • The Moving Average Convergence/Divergence (MACD) is 0.071. The Moving Average Convergence/Divergence (MACD) above zero is a bullish sign. +1
  • The MACD is lower than the signal line. This is a bearish indication. -1
Akebia Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAkebia Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
1.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).

The ADX helps you determine the strength of a trend. Let's take a look of the ADX of Akebia Therapeutics Inc:

  • The ADX is 28.356. Strong Trend. +1
  • The ADX is declining, the current trend is weakening. -1
  • The +DI crossed the -DI to the upside. The trend is reversing to an up trend. +1
Akebia Therapeutics Inc Daily Directional Movement Index (DMI) ChartAkebia Therapeutics Inc Daily Directional Movement Index (DMI) Chart
1.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..
  • The Parabolic SAR is higher than the price. The current trend is down. -2
  • Akebia Therapeutics Inc Daily Parabolic SAR ChartAkebia Therapeutics Inc Daily Parabolic SAR Chart

    2. Momentum Indicators

    2.1 Relative Strength Index (RSI)

    Measures the speed and change of price movements.

    • Leading momentum indicator, meaning the signals are instant.
    • Ranges between 0 and 100.
    • Above 70 is considered overbought.
    • Below 30 is considered oversold.
    • Above or below 50 can also be used to determine price trend or support and resistance.
    • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
    • Can be used in many different ways
    • The RSI is above 50. +1
    Akebia Therapeutics Inc Daily Relative Strength Index (RSI) ChartAkebia Therapeutics Inc Daily Relative Strength Index (RSI) Chart
    2.2 Stochastic Oscillator

    Compares a certain price to multiple prices ranging over time.

    • Leading momentum indicator, meaning the signals are instant.
    • Used to determine overbought and oversold areas much like the RSI.
    • Ranges between 0 and 100.
    • Above 80 is considered overbought.
    • Below 20 is considered oversold.
    • Consists of two lines named K and D.
    • K compares the highest high and lowest low on the selected price range.
    • The D line is a moving average of the K line.
    • Can be used to spot divergences
    • The Stochastic is below 50. -1
    • The Stochastic is below 30 and oversold. +2
    Akebia Therapeutics Inc Daily Stochastic Oscillator ChartAkebia Therapeutics Inc Daily Stochastic Oscillator Chart
    2.3 Commodity Channel Index (CCI)
    Akebia Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAkebia Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
    2.4 Chande Momentum Oscillator (CMO)
    Akebia Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAkebia Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
    2.5 Williams %R
    Akebia Therapeutics Inc Daily Williams %R ChartAkebia Therapeutics Inc Daily Williams %R Chart

    3. Volatility Indicators

    3.1 Bollinger Bands
    Akebia Therapeutics Inc Daily Bollinger Bands ChartAkebia Therapeutics Inc Daily Bollinger Bands Chart
    3.2 Average True Range (ATR)
    Akebia Therapeutics Inc Daily Average True Range (ATR) ChartAkebia Therapeutics Inc Daily Average True Range (ATR) Chart

    4. Volume Indicators

    4.1 On-Balance Volume (OBV)
    Akebia Therapeutics Inc Daily On-Balance Volume (OBV) ChartAkebia Therapeutics Inc Daily On-Balance Volume (OBV) Chart
    4.2 Money Flow Index (MFI)
    Akebia Therapeutics Inc Daily Money Flow Index (MFI) ChartAkebia Therapeutics Inc Daily Money Flow Index (MFI) Chart

    5. Summary

    5.1. Notifications

    TypeNotificationDate
    PenkeCurrently no notifications for Akebia Therapeutics Inc.

    5.2. Trading Signals

    DateIndicatorEntry signalExit signal
    2023-05-19 00:00:00ATR SHORT ENTRY LONG CLOSE
    2023-05-22 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
    ATR SHORT ENTRY LONG CLOSE
    2023-05-23 00:00:00CMO LONG ENTRY SHORT CLOSE50 crossover to upside
    2023-05-24 00:00:00CMO LONG ENTRY SHORT CLOSE50 crossover to upside
    2023-05-25 00:00:00SAR LONG ENTRY SHORT CLOSEprice crossed sar to upside
    CCI LONG ENTRY SHORT CLOSE100 crossover to upside
    CMO LONG ENTRY SHORT CLOSE50 crossover to upside
    WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
    ATR LONG ENTRY SHORT CLOSE
    2023-05-26 00:00:00ATR LONG ENTRY SHORT CLOSE
    2023-05-29 00:00:00MACD SHORT ENTRY LONG CLOSE
    2023-05-30 00:00:00DMI LONG ENTRY SHORT CLOSE
    STOCH LONG ENTRY SHORT CLOSE20 crossover to upside
    ATR LONG ENTRY SHORT CLOSE
    2023-05-31 00:00:00DMI SHORT ENTRY LONG CLOSE
    ATR SHORT ENTRY LONG CLOSE

    5.2. Technical Score

    Let's check the technical score of Akebia Therapeutics Inc based on Penke's default Symbol scanner.

    Penke's Symbol Scanner

      
      
    IndicatorConditionValue
    RsiGreater than5050.483
    Ma 20Greater thanMa 501.028
    Ma 50Greater thanMa 1000.776
    Ma 100Greater thanMa 2000.757
    OpenGreater thanClose0.965
    Total4/5 (80.0%)

    Comments

    Join the conversation.

    Leave a comment

    Stay informed about Akebia Therapeutics Inc.

    Receive notifications about Akebia Therapeutics Inc in your mailbox!

    Penke's Market Notifications
    XMLC.XETRA
    now

    I found you a Golden Cross on the daily chart of XMLC.XETRA.

    XMLC.XETRA Daily Candlestick Chart
    JCHE.XETRA
    2 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of JCHE.XETRA.

    JCHE.XETRA Daily Candlestick Chart
    NK4L.XETRA
    2 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of NK4L.XETRA.

    NK4L.XETRA Daily Candlestick Chart
    METV.XETRA
    20 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of METV.XETRA.

    METV.XETRA Daily Candlestick Chart
    KTN.XETRA
    22 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of KTN.XETRA.

    KTN.XETRA Daily Candlestick Chart
    ECMS.XETRA
    22 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of ECMS.XETRA.

    ECMS.XETRA Daily Candlestick Chart
    XDPU.XETRA
    22 minutes ago

    I found you a Golden Cross on the daily chart of XDPU.XETRA.

    XDPU.XETRA Daily Candlestick Chart
    JCGA.LSE
    24 minutes ago

    I found you a Oversold RSI (Relative Strength Index) on the daily chart of JCGA.LSE.

    JCGA.LSE Daily Candlestick Chart
    JCAS.LSE
    24 minutes ago

    I found you a Oversold RSI (Relative Strength Index) on the daily chart of JCAS.LSE.

    JCAS.LSE Daily Candlestick Chart
    JCAP.LSE
    24 minutes ago

    I found you a Oversold RSI (Relative Strength Index) on the daily chart of JCAP.LSE.

    JCAP.LSE Daily Candlestick Chart
    SZU.XETRA
    24 minutes ago

    I found you a Oversold RSI (Relative Strength Index) on the daily chart of SZU.XETRA.

    SZU.XETRA Daily Candlestick Chart
    EQQD.LSE
    26 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of EQQD.LSE.

    EQQD.LSE Daily Candlestick Chart
    H4ZN.XETRA
    26 minutes ago

    I found you a Golden Cross on the daily chart of H4ZN.XETRA.

    H4ZN.XETRA Daily Candlestick Chart
    CBUN.XETRA
    26 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of CBUN.XETRA.

    CBUN.XETRA Daily Candlestick Chart
    DRGG.LSE
    28 minutes ago

    I found you a Oversold RSI (Relative Strength Index) on the daily chart of DRGG.LSE.

    DRGG.LSE Daily Candlestick Chart
    I500.XETRA
    28 minutes ago

    I found you a Golden Cross on the daily chart of I500.XETRA.

    I500.XETRA Daily Candlestick Chart
    FUSR.XETRA
    28 minutes ago

    I found you a Golden Cross on the daily chart of FUSR.XETRA.

    FUSR.XETRA Daily Candlestick Chart
    XNGI.XETRA
    30 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of XNGI.XETRA.

    XNGI.XETRA Daily Candlestick Chart
    WELX.XETRA
    30 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of WELX.XETRA.

    WELX.XETRA Daily Candlestick Chart
    V3YA.XETRA
    30 minutes ago

    I found you a Golden Cross on the daily chart of V3YA.XETRA.

    V3YA.XETRA Daily Candlestick Chart
    FLRA.XETRA
    32 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of FLRA.XETRA.

    FLRA.XETRA Daily Candlestick Chart
    SPBSESN50.INDX
    36 minutes ago

    I found you a Golden Cross on the daily chart of SPBSESN50.INDX.

    SPBSESN50.INDX Daily Candlestick Chart
    NSEI.INDX
    36 minutes ago

    I found you a Golden Cross on the daily chart of NSEI.INDX.

    NSEI.INDX Daily Candlestick Chart
    NIFTYHEALTHCARE.INDX
    36 minutes ago

    I found you a Overbought RSI (Relative Strength Index) on the daily chart of NIFTYHEALTHCARE.INDX.

    NIFTYHEALTHCARE.INDX Daily Candlestick Chart
    MCILEAD.INDX
    38 minutes ago

    I found you a Oversold RSI (Relative Strength Index) on the daily chart of MCILEAD.INDX.

    MCILEAD.INDX Daily Candlestick Chart